Ann: Cellmid to Commence Selling of Evolis into Chinese Market, page-70

So instead of making one big post I thought I'll  just point out a few things about Fukangren/Fogangren/阜康仁  on occasion. More to come - maybe.... While the information is freely and easily available online, it's always worth pointing out interesting aspects.

Fukangren's Partners (en.fukangren.com/hezuohuoban.html)



I believe that Cellmid's Fukangren partnership will let them take advantage of Fukangren's partners as well. For those who haven't seen it yet, their partner under "commercialisation" is Reyoung (Reiyoung/Rei Young/Re Young/Ruiyoung/瑞阳). I believe that this is a significant detail. Why?


Yup, it's Fukangren's  strategic partner for product commercialisation. They mention that they "closely"  cooperate, as well as their sales network and marketing team.

https://translate.google.com.au/translate?sl=zh-CN&tl=en&js=y&prev=_t&hl=en&ie=UTF-8&u=http://www.fukangren.com/shangyehua.html&edit-text=

Reyoung is quite a big fish:
Here is a presentation about Reyoung (file modification date January 2018):
https://www.pharmacompass.com/jAssets/pdf/party/Reyoung-pharmaceutical-Co-Ltd-1514965441.pdf

They say they have net assets of US $750 million.



In addition, Fukangren has a partnership with Portuguese BluePharma (https://www.bluepharma.pt/)

BluePharma are looking for distribution deals as well ("We Are Interested"):


Noteworthy: "Finished product supply", "collaborates with large pharmaceutical companies".

Further (from Wikipedia):
Bluepharma has clients in Portugal, France, Germany and in the UK, among others. One of Bluepharma's main clients is Bayer to which the Portuguese company produced around 3.5 million units in 2004. Other clients include pharmaceuticals brands and companies such as Teva, Ivax, Arrow, EG LABO (Stada), Bexal (Hexal), Mepha (Ratiopharm) and Ciclum (Grünenthal).

Source: https://en.wikipedia.org/wiki/Bluepharma

These partnerships could be a valuable connection when Europe is being approached as well. And that is only for Cellmid's FDF5 invhibitor line évolis^™ PROFESSIONAL.

Cellmid's partnership with Fukangren might be more valuable than one might think... particularly once Cellmid actually starts going clinical with MIDKINE assets...